Press release
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that preclinical data for a conditionally activated interferon alpha-2b (IFN-a2b) will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (SITC 2021) taking place November 12-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. “Cytokines are powerful immune modulators with much potential for the treatment of cancer. We are excited to showcase the preclinical safety and anti-cancer activity of our conditionally activated interferon, highlighting the versatility and robust therapeutic potential of CytomX Probody-based biologics,” stated Marcia P. Belvin, Ph.D., senior vice president and head of research of CytomX Therapeutics. Details on CytomX’s poster presentation at SITC 2021 are as follows:Presentation Title: Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2bAbstract: 706 About CytomX TherapeuticsCytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb. Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic ca...